This is one of the best articles on statins and Alzheimer’s that I have ever read.
It is written by a prominent professor of neurology at USC who is actively doing research on APOE4.
I highly recommend reading this.
Louis recommends an article by USC neurologist Hussein Yassine on whether APOE4 carriers should take statins. It argues the case for statins is vascular prevention, and that APOE4/4 carriers with high LDL deserve careful individual discussions on evidence, risk profile and family history.
This is one of the best articles on statins and Alzheimer’s that I have ever read.
It is written by a prominent professor of neurology at USC who is actively doing research on APOE4.
I highly recommend reading this.
To Statin or Not To Statin for Alzheimer's? Why the best case for statins in APOE4 is vascular prevention, not Alzheimer’s treatment.
yassinelab.orgTo Statin or Not To Statin for Alzheimer's?Why the best case for statins in APOE4 is vascular, not “Alzheimer’s treatment”yassinelab.org
You may have a very strongly-held answer to the question in the title.
But what if the answer depends on who you are: a patient with a diagnosis of MCI or Alzheimer's, or someone with ApoE 4/4 and high LDL?
Below is a summary of a Substack post from an APOE4 researcher who thinks HOW we think about this question is important AND that APOE 4 carriers deserve careful discussions with providers about the evidence, their preferences, personal cardiovascular risk profile, family history and expectations.
Dr. Hussein Yassine, Professor of Neurology at Keck School of Medicine of USC, directs a lab that specializes in studying how carrying the APOE4 allele affects lipid metabolism, neuroinflammation and the risk of developing late-onset Alzheimer’s disease.
Dr. Yassine also directs the USC Center for Personalized Brain Health (USC Center for Personalized Brain Health (Center for Personalized Brain Health)) focused on understanding mechanisms and risk factors of dementia in patients carrying the APOE4 allele.He presents questions from a hypothetical 65-year old with APOE 4/4 who is lean, exercises at least five days per week, and has a heart-healthy diet, with a family history of a mother who developed dementia in her late 70's and an LDL level of 175 mg/dL
⭐ If an APOE4/4 carrier has elevated LDL but no dementia, does lowering LDL with a statin meaningfully help brain health? How can we together read the evidence with their real-world decision in mind?
🔹 ApoE is a lipid transport gene. One practical consequence is that APOE4, especially APOE4/4, shifts lipid handling in ways that can raise LDL, even in people who eat well and exercise consistently. In real life, genotype can constrain physiology even when behavior is optimal.
🔹APOE4 is a vascular risk gene. Large population data support that APOE4 is associated not only with dementia risk but also with vascular disease. Vascular injury, clinical stroke and “silent” small vessel disease, can lower cognitive reserve and amplify neurodegenerative trajectories.
❤️ This may be a cognitive frame shift for the hypothetical ApoE 4/4 carrier: their LDL cholesterol level may be partially genetic, and its relevance to brain health may be as much, or possibly more, vascular prevention than direct Alzheimer prevention.
🔹 Genetic epidemiology signals: direction-of-effect, not proof.
When randomized prevention trials are difficult, researchers often turn to genetic epidemiology, looking at observations of large groups to test whether a risk factor plausibly sits upstream of disease. So the honest interpretation is: there are credible signals suggesting subgroup benefit (notably in APOE4), but they are not definitive. Using trials to define causality is difficult: the takeaway is plausibility, not certainty.
🔹What about statins in people with a diagnosis of MCI or Alzheimer's dementia?
➤ If you only looked at randomized trials in people with established Alzheimer’s disease, you might walk away thinking the case is closed: statins do not help.
➤ But they answer a treatment question: Do statins help after a diagnosis of MCI/AD? (Apparently not.)
➤ One important finding from these trials is that even in patients with AD, statins do not worsen memory (more on that below).
⭐ The prevention question still is: Does decades of lower LDL reduce the probability of reaching symptomatic disease?
🔹But the first question for some might be;"Do statins worsen memory in cognitively normal people?”
Here Dr. Yassine offers both rigorous data and some real-world clinical advice.
➤ In the PROSPER trial with 5,804 participants, aged 70 to 82, randomized to pravastatin vs placebo, detailed cognitive outcomes were assessed repeatedly and did not support a clinically meaningful adverse effect on cognition attributable to pravastatin.
➤ A practical way to say this is: the best available evidence does not support the claim that statins generally worsen memory. If a specific patient experiences cognitive symptoms with a medication, that should be evaluated carefully, but it should not be assumed to be the expected or typical effect.
🔹Lipophilic vs. hydrophilic statins
Statins differ in chemical properties that influence distribution. Lipophilic statins are often discussed as having greater potential CNS penetration, while hydrophilic statins are generally more hepatoselective and do not enter the brain.
[Side Note: The predominantly lipophilic statins are simvastatin, fluvastatin, pitavastatin, lovastatin and atorvastatin; hydrophilic statins include rosuvastatin and pravastatin.]
Does this translate into meaningfully different dementia outcomes? The evidence is not definitive, but large observational datasets have explored the question. A reasonable scientific posture: drug class and combinations of statins with anti-hypertensives are plausible modifiers, and the question deserves prospective testing
🔹Dr. Yassine suggest that two goals should be kept separate:
➤ Risk modification: lowering LDL and reducing vascular events, which plausibly supports brain resilience.
➤ Disease modification: changing core Alzheimer’s pathology trajectories (amyloid, tau, neurodegeneration).
❤️ A patient-centered, person-focused conversation, in Dr. Yassine's words:
"What can be said responsibly, based on the evidence reviewed, is that an LDL of 175 mg/dL at age 65 commonly triggers a clinician-patient discussion about lipid-lowering for vascular risk reduction. APOE4/4 and family history make the prevention context more salient, but they do not turn statins into a proven dementia-prevention drug."
"The decision belongs in a discussion with his clinician that incorporates his overall cardiovascular risk profile, family history, preferences, and tolerance, while keeping expectations calibrated: the clearest benefit is vascular, the long-term dementia prevention-related benefit is plausible but not proven."
Dr. Yassine has a clear recommendation going forward::
🔹Newer trials for brain outcomes using statins should consider more brain biomarkers than cognition during the pre-dementia phases, and especially those that reflect the effects of statins on the brain.
You. can read Dr. Yassine's Substack on the link.